Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.69
DCTH's Cash-to-Debt is ranked lower than
72% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. DCTH: 0.69 )
Ranked among companies with meaningful Cash-to-Debt only.
DCTH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.33  Med: No Debt Max: No Debt
Current: 0.69
Equity-to-Asset -0.02
DCTH's Equity-to-Asset is ranked lower than
96% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. DCTH: -0.02 )
Ranked among companies with meaningful Equity-to-Asset only.
DCTH' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.04  Med: 0.71 Max: 0.84
Current: -0.02
-0.04
0.84
Piotroski F-Score: 3
Altman Z-Score: -13.67
Beneish M-Score: -6.59
WACC vs ROIC
136.73%
-581.49%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -726.85
DCTH's Operating Margin % is ranked lower than
93% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. DCTH: -726.85 )
Ranked among companies with meaningful Operating Margin % only.
DCTH' s Operating Margin % Range Over the Past 10 Years
Min: -15569.65  Med: -1805.8 Max: -726.85
Current: -726.85
-15569.65
-726.85
Net Margin % -1162.37
DCTH's Net Margin % is ranked lower than
93% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. DCTH: -1162.37 )
Ranked among companies with meaningful Net Margin % only.
DCTH' s Net Margin % Range Over the Past 10 Years
Min: -14990.75  Med: -1625.91 Max: -841.67
Current: -1162.37
-14990.75
-841.67
ROE % -875.59
DCTH's ROE % is ranked lower than
96% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. DCTH: -875.59 )
Ranked among companies with meaningful ROE % only.
DCTH' s ROE % Range Over the Past 10 Years
Min: -875.59  Med: -116.48 Max: -29.88
Current: -875.59
-875.59
-29.88
ROA % -87.45
DCTH's ROA % is ranked lower than
90% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. DCTH: -87.45 )
Ranked among companies with meaningful ROA % only.
DCTH' s ROA % Range Over the Past 10 Years
Min: -157.86  Med: -73.22 Max: -27.27
Current: -87.45
-157.86
-27.27
ROC (Joel Greenblatt) % -153.40
DCTH's ROC (Joel Greenblatt) % is ranked lower than
91% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. DCTH: -153.40 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DCTH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5031.97  Med: -924.86 Max: -79.11
Current: -153.4
-5031.97
-79.11
3-Year Revenue Growth Rate -15.10
DCTH's 3-Year Revenue Growth Rate is ranked higher than
51% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. DCTH: -15.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DCTH' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 6.1
Current: -15.1
0
6.1
3-Year EBITDA Growth Rate -69.70
DCTH's 3-Year EBITDA Growth Rate is ranked lower than
99% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. DCTH: -69.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DCTH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -69.7  Med: -11.8 Max: 56.4
Current: -69.7
-69.7
56.4
3-Year EPS without NRI Growth Rate -49.40
DCTH's 3-Year EPS without NRI Growth Rate is ranked lower than
98% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. DCTH: -49.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DCTH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -59.3  Med: -16.7 Max: 95.7
Current: -49.4
-59.3
95.7
GuruFocus has detected 2 Warning Signs with Delcath Systems Inc $DCTH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DCTH's 30-Y Financials

Financials (Next Earnings Date: 2017-08-16 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

DCTH Guru Trades in Q2 2016

Jim Simons 754,998 sh (+10.62%)
» More
Q3 2016

DCTH Guru Trades in Q3 2016

Jim Simons 59,914 sh (+26.97%)
» More
Q4 2016

DCTH Guru Trades in Q4 2016

Jim Simons 160,128 sh (+167.26%)
» More
Q1 2017

DCTH Guru Trades in Q1 2017

Jim Simons 674,114 sh (+320.98%)
» More
» Details

Insider Trades

Latest Guru Trades with DCTH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 621511    SIC: 3841
Compare:OTCPK:YBAO, OTCPK:ADMD, OTCPK:ULUR, OTCPK:ACUR, OTCPK:RSPI, OTCPK:NUVPF, OTCPK:BLONF, OTCPK:NRXCF, OTCPK:LBLTF, OTCPK:PUFXF, AMEX:IGC, OTCPK:AQSZF, NAS:APRI, OTCPK:RLMD, NAS:MYOS, OTCPK:AOLS, OTCPK:CBICF, OTCPK:PVCT, OTCPK:CYIG, OTCPK:PARNF » details
Traded in other countries:DV32.Germany,
Headquarter Location:USA
Delcath Systems Inc is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Its products include Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System.

Delcath Systems Inc is a Delaware corporation, incorporated on August 5, 1988. The Company is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. It is a specialty pharmaceutical and medical device company developing its proprietary product-Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). In Europe, its proprietary system to deliver and filter melphalan hydrochloride is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). Its primary focus is on the execution of its clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver), and certain other cancers that are metastatic to the liver. The Company currently operates in one business segment, which is the development and commercialization of CHEMOSAT/Melphalan/HDS. Its competitors include Covidian, Biocompatibles, Merit, CeleNova, SirTex, AngioDynamics, and many others. The Company currently holds eight U.S. utility patents, one U.S. design patent, six pending U.S. utility patent applications (one of which has been allowed), four issued foreign counterpart utility patents, six issued foreign counterpart design patents, and eight pending foreign counterpart patent applications (one of which has been allowed). The Company's products are subject to extensive and rigorous government regulation by foreign regulatory agencies and the FDA.

Top Ranked Articles about Delcath Systems Inc

Delcath Issues Letter to Stockholders
Spire Southampton Hospital in UK Celebrating Over 100 CHEMOSAT Treatments
Delcath Announces Special Protocol Assessment Agreement With FDA for Pivotal Trial With Melphalan/HDS in Intrahepatic Cholangiocarcinoma

Company Plans to file 2016 Fourth Quarter and Year End Financial Results by March 30, 2017

NEW YORK, March 27, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces it has reached a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the design of Delcath’s pivotal trial of Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) to treat patients with intrahepatic cholangiocarcinoma (ICC). The SPA agreement indicates that the pivotal trial design adequately addresses objectives that, if met, would support regulatory requirements for approval of Melphalan/HDS.
The pivotal trial is titled “A Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine versus Cisplatin/Gemcitabine (Standard of Care) in Patients with Intrahepatic Cholangiocarcinoma.”  Under the SPA, the study will enroll approximately 295 ICC patients at approximately 40 clinical sites in the U.S. and Europe.  The primary endpoint is overall survival (OS) and secondary and exploratory endpoints include safety, progression-free survival (PFS), overall response rate (ORR) and quality-of-life measures. The Company expects to initiate the study in the Fall of 2017. Full details of the registration trial will be made public upon the launch of the study and will be available at www.clinicaltrials.gov.  “We look forward to initiating this important study in ICC under a SPA with the FDA,” said Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcath. “The promising outcomes and observations in this tumor type identified by European investigators at our global Key Opinion Leader Forum last year were discussed at length with the agency, and provide us with considerable confidence in the potential of our therapy as a treatment for ICC. A manuscript of the European investigator data will be submitted to a peer-reviewed journal for publication."   “This pivotal study in ICC is designed to be cost effective and pursued in a financially prudent manner.  Given the sequential nature of the trial design, Delcath’s investment in this study will be modest in 2017 as the Melphalan/HDS segment of the study will not occur until late in the year," added Dr. Simpson. Separately, the Company announces that it intends to file financial results for the three and 12 months ending December 31, 2016 on Form 10-K with the U.S. Securities and Exchange Committee on or before March 30, 2017. About Special Protocol Assessments 
The Special Protocol Assessment (SPA) process is a procedure by which the FDA provides official evaluation and written guidance on the design and size of proposed protocols that are intended to form the basis for a new drug application. Final marketing approval depends on the results of efficacy, the adverse event profile and an evaluation of the benefit/risk of treatment demonstrated in the Phase 3 clinical program. The SPA agreement may only be changed through a written agreement between the sponsor and the FDA, or if the FDA becomes aware of a substantial scientific issue essential to product efficacy or safety. About Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma is the second most common primary liver tumor and represents approximately 10-20% of new hepatocellular carcinoma (primary liver cancer or HCC) cases diagnosed annually, or approximately 3,100 new cases every year in the U.S.1 Surgical resection, the standard of care, is not possible for an estimated 80% to 90% of patients diagnosed with ICC. About Delcath Systems
Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Our investigational product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) —is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. We have commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM) and plan to initiate a Registration trial for intrahepatic cholangiocarcinoma (ICC) in the Fall of 2017. Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S.  In Europe, our system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver. Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to:  the timing and results of the Company’s  clinical trials including without limitation the OM and ICC  clinical trial programs  timely enrollment and treatment of patients in the global Phase 3 OM clinical trial, , IRB or ethics committee clearance of the  Phase 3 OM and ICC Registration trial  protocols from  participating sites and the timing of site activation and subject enrollment in each trial, the impact of the presentations at major medical conferences and future clinical results consistent with the data presented, approval of Individual Funding Requests for reimbursement of the CHEMOSAT procedure, the impact, if any  of ZE reimbursement on potential CHEMOSAT product use and sales in Germany, clinical adoption, use and resulting sales, if any, for the CHEMOSAT system to deliver and filter melphalan in Europe including the key markets of Germany and the UK, the Company’s ability to successfully commercialize the Melphalan HDS/CHEMOSAT system and the potential of the Melphalan HDS/CHEMOSAT system as a treatment for patients with primary and metastatic disease in the liver, our ability to obtain reimbursement for the CHEMOSAT system in various markets,, approval of the current or future Melphalan HDS/CHEMOSAT system for delivery and filtration of melphalan or other chemotherapeutic agents for various indications in the U.S. and/or in foreign markets, actions by the FDA or other foreign regulatory agencies, the Company’s ability to successfully enter into strategic partnership and distribution arrangements in foreign markets and the timing and revenue, if any, of the same, uncertainties relating to the timing and results of research and development projects, our ability to maintain NASDAQ listing, and uncertainties regarding the Company’s ability to obtain financial and other resources for any research, development, clinical trials and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made. 1 M. Tucker “Model Predicts Survival in Intrahepatic Cholangiocarcinoma”  http://www.medscape.com/viewarticle/821759 (Accessed March 24, 2017) 
Contact Information:
David Boral
Managing Director
CoreIR
Tel: 516 222 2560
Email:[email protected]

Read more...
Delcath Systems To Present At ROTH Capital Partners 29th Annual Growth Stock Conference On March 13, 2017

NEW YORK, March 10, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, today announced that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcath will be a featured presenter at the ROTH Capital Partners 29th Annual Growth Stock Conference on Monday, March 13, 2017 at 7:30 AM Pacific Time in BLUE - SALON 2 at the Ritz-Carlton Laguna Niguel, CA.
Dr. Simpson will highlight the recent corporate developments and provide an overview of the Company. A live webcast of the presentation will be available at http://delcath.com/investors-events/ and a webcast replay will be available at the same address approximately one hour after the live webcast presentation for 90 days. Please log in approximately 5-10 minutes before the event to ensure a timely connection. Management will be available for one-on-one meetings with investors throughout the conference. About Delcath Systems Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Our investigational product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) —is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. We have commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM) and a global Phase 2 clinical trial in Europe and the U.S. to investigate the Melphalan/HDS system for the treatment of primary liver cancer (HCC) and intrahepatic cholangiocarcinoma (ICC). Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S.  In Europe, our system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver. Forward-Looking Statements: Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to: our ability to repay and comply with the obligations under our senior secured convertible notes, the timing and results of the Company's  clinical trials including without limitation the OM, HCC, and  ICC clinical trial programs,  timely enrollment and treatment of patients in the global Phase 3 FOCUS Clinical Trial for Patients with Hepatic Dominant Ocular Melanoma and the global Phase 2 HCC and ICC clinical trials, IRB or ethics committee clearance of the Phase 2 HCC/ICC  and/or Phase 3 OM  protocols from  participating sites and the timing of site activation and subject enrollment in each trial, the impact, if any, of publication of the Phase 3 trial manuscript to support the Company's efforts, the impact of the presentations at major medical conferences and future clinical results consistent with the data presented, the impact, if any  of ZE reimbursement on potential CHEMOSAT product use and sales in Germany, clinical adoption, use and resulting sales, if any, for the CHEMOSAT system to deliver and filter melphalan in Europe, the Company's ability to successfully commercialize the CHEMOSAT/Melphalan HDS system and the potential of the CHEMOSAT/Melphalan HDS system as a treatment for patients with primary and metastatic disease in the liver, our ability to obtain reimbursement for the CHEMOSAT system in various markets, the Company's ability to satisfy the remaining requirements of the FDA's Complete Response Letter and provide the same in a timely manner, approval of the current or future Melphalan HDS/CHEMOSAT system for delivery and filtration of melphalan for various indications in the U.S. and/or in foreign markets, actions by the FDA or other foreign regulatory agencies, the Company's ability to successfully enter into strategic partnership and distribution arrangements in foreign markets and the timing and revenue, if any, of the same, uncertainties relating to the timing and results of research and development projects, our ability to maintain NASDAQ listing, and uncertainties regarding the Company's ability to obtain financial and other resources for any research, development, clinical trials and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.
Contact Information:
David Boral
Managing Director
CORE IR
Tel: 516 222 2560
Email: [email protected]

Read more...

Ratios

vs
industry
vs
history
PS Ratio 0.02
DCTH's PS Ratio is ranked higher than
100% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. DCTH: 0.02 )
Ranked among companies with meaningful PS Ratio only.
DCTH' s PS Ratio Range Over the Past 10 Years
Min: 0.02  Med: 11.95 Max: 1044.69
Current: 0.02
0.02
1044.69
Current Ratio 0.97
DCTH's Current Ratio is ranked lower than
84% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. DCTH: 0.97 )
Ranked among companies with meaningful Current Ratio only.
DCTH' s Current Ratio Range Over the Past 10 Years
Min: 0.58  Med: 5.74 Max: 67.13
Current: 0.97
0.58
67.13
Quick Ratio 0.94
DCTH's Quick Ratio is ranked lower than
73% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. DCTH: 0.94 )
Ranked among companies with meaningful Quick Ratio only.
DCTH' s Quick Ratio Range Over the Past 10 Years
Min: 0.58  Med: 5.74 Max: 67.13
Current: 0.94
0.58
67.13
Days Inventory 412.04
DCTH's Days Inventory is ranked lower than
97% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. DCTH: 412.04 )
Ranked among companies with meaningful Days Inventory only.
DCTH' s Days Inventory Range Over the Past 10 Years
Min: 412.04  Med: 669.79 Max: 5170.83
Current: 412.04
412.04
5170.83
Days Sales Outstanding 59.57
DCTH's Days Sales Outstanding is ranked higher than
53% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. DCTH: 59.57 )
Ranked among companies with meaningful Days Sales Outstanding only.
DCTH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 57.87  Med: 73.84 Max: 161.25
Current: 59.57
57.87
161.25
Days Payable 387.74
DCTH's Days Payable is ranked higher than
82% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.53 vs. DCTH: 387.74 )
Ranked among companies with meaningful Days Payable only.
DCTH' s Days Payable Range Over the Past 10 Years
Min: 224.37  Med: 457.82 Max: 8788.08
Current: 387.74
224.37
8788.08

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -99.20
DCTH's 3-Year Average Share Buyback Ratio is ranked lower than
95% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. DCTH: -99.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DCTH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -99.2  Med: -27.45 Max: -12.6
Current: -99.2
-99.2
-12.6

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % -62.47
DCTH's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. DCTH: -62.47 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DCTH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -62.5  Med: 272.1 Max: 190327.2
Current: -62.47
-62.5
190327.2

More Statistics

Revenue (TTM) (Mil) $2.37
EPS (TTM) $ -9.53
Beta1.49
Short Percentage of Float7.53%
52-Week Range $0.02 - 6.49
Shares Outstanding (Mil)167.88
» More Articles for DCTH

Headlines

Articles On GuruFocus.com
Delcath Issues Letter to Stockholders Apr 27 2017 
Spire Southampton Hospital in UK Celebrating Over 100 CHEMOSAT Treatments Apr 18 2017 
Delcath Announces Special Protocol Assessment Agreement With FDA for Pivotal Trial With Melphalan/HD Mar 27 2017 
Delcath Systems To Present At ROTH Capital Partners 29th Annual Growth Stock Conference On March 13, Mar 10 2017 
Five NCAV Companies for Value Investors – August 2015 Aug 04 2015 
Weekly CFO Buys Highlight: BWEN, EMC, INO, DCTH, ACCO Jun 11 2012 
Delcath Systems Inc. Reports Operating Results (10-Q) Oct 23 2009 

More From Other Websites
Delcath Announces First Quarter 2017 Financial Results May 09 2017
Delcath Issues Letter to Stockholders Apr 27 2017
Spire Southampton Hospital in UK Celebrating Over 100 CHEMOSAT Treatments Apr 18 2017
Delcath Announces 2016 Financial Results Mar 29 2017
Delcath Clinical Study Design Approved By FDA Mar 27 2017
Delcath Announces Special Protocol Assessment Agreement With FDA for Pivotal Trial With... Mar 27 2017
Delcath Systems To Present At ROTH Capital Partners 29th Annual Growth Stock Conference On March 13,... Mar 10 2017
Delcath Systems to Present at the 2nd Annual Disruptive Growth & Healthcare Conference Feb 06 2017
Delcath Systems To Present At The NobleCon13 - Noble Capital Markets' Thirteenth Annual Investor... Jan 23 2017
New Outcomes Data Using Delcath's Melphalan/HDS To Treat Unresectable Metastatic Ocular Melanoma To... Jan 18 2017
Delcath Announces Ongoing Patient Treatment And Data Collection In Intrahepatic Cholangiocarcinoma... Jan 12 2017
DryShips, Merrimack Tumble into Friday’s 52-Week Low Club Jan 06 2017
Delcath Systems, Inc. :DCTH-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016 Nov 14 2016
Review Of Delcath's CHEMOSAT Accepted For Publication In Advances In Therapy Oct 17 2016
Delcath Announces New U.S. Clinical Sites For FOCUS Phase 3 Trial For Ocular Melanoma Liver... Oct 11 2016
Here’s Why These Five Stocks Are on the Move Today Sep 30 2016
Delcath Prices Underwritten Public Offering of Common Stock and Warrants Sep 30 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)